The term „biologics” is usually used for a class of medications (either approved or in development) that are produced by means of biological processes involving recombinant DNA technology. These medications are divided one of three types – key siganalling proteins (e.g. erythropoetin), monoclonal antibodies, receptor constructors. It was showed in many clinical studies that biologics have added therapeutic options for the treatment of many diseases in the fields of rheumatology, oncology, dermatology, pneumonology, and others. However the access to these medicines is different across European countries and depends on many concerns, including adverse events, complex regulatory issues, pharmacoeconomic aspects. The problems of biologics treatment in Poland and across Europe are discussed in this article.